February 08, 2017

A “release and kill” strategy may aid treatment of tuberculosis

Written by

jim sun 2017Jim Sun, Ph.D.Mycobacterium tuberculosis has been called “the perfect pathogen.” These bacteria hijack human macrophages, persist inside the cells to evade immune destruction, and then prevent the macrophage from undergoing programmed cell death. This provides a niche where they grow in a protected environment that is hard to reach with antibiotics.

An end to that hijacking may now be possible, as University of Alabama at Birmingham researchers explain in the journal Scientific Reports. In a proof-of-concept experiment, they were able to specifically force M. tuberculosis-infected macrophages into programmed cell death called apoptosis, thereby releasing the sheltered M. tuberculosis bacteria from the macrophage. The released pathogenic bacteria could then be killed by a lower concentration of rifampicin, one of the front-line tuberculosis antibiotics that is ineffective against the sheltered intracellular bacteria.

This strategy has been dubbed “release and kill,” by Jim Sun, Ph.D., and colleagues, and if developed to clinical application, it could mean greatly shortened treatment periods for patients with tuberculosis, which now last at least six months. Their preclinical findings show, for the first time, that drug-induced selective apoptosis of M. tuberculosis-infected macrophages is achievable. Furthermore, drug-induced apoptosis could also improve the adaptive immune response against the pathogen and potentiate vaccines.

More than 10 million people develop active tuberculosis disease each year, and 1.8 million die.

This latest paper expands upon seminal results published by Sun and colleagues last year. They identified a macrophage enzyme called PPM1A as a central component of both the antiviral and antibacterial responses of macrophages. When M. tuberculosis infects macrophages, they found that it induced the upregulation of PPM1A, which in turn caused what Sun called “immune paralysis” of the macrophages.

This strategy has been dubbed “release and kill,” by Jim Sun, Ph.D., and colleagues, and if developed to clinical application, it could mean greatly shortened treatment periods for patients with tuberculosis, which now last at least six months.

Specifically, the heightened PPM1A levels abrogated the ability of macrophages to send out an “alarm signal” (the efficient production of cytokines and chemokines) in response to pathogen-associated molecules like lipopolysaccharide, it blocked the rush to the “scene of the fire” (migration of macrophages in response to a chemotactic signal of infection from other cells), and it prevented the macrophage’s ability to “put out the fire” (by impairing the macrophage’s capacity to engulf, or phagocytose, bacteria, the first step in the normal defense against bacterial infections).

In this latest Scientific Reports paper, the UAB researchers greatly expand their understanding of PPM1A’s role beyond immune paralysis. They show how the abnormal upregulation of this macrophage enzyme provoked by M. tuberculosis acts as a checkpoint that ends the macrophage’s ability to undergo both intrinsic and extrinsic apoptosis.

Apoptosis is a normal, daily event. Between 50 billion and 70 billion cells in an adult undergo apoptotic death every day. Intrinsic apoptosis responds to a signal of cell aging or dysfunction from the inside, and extrinsic apoptosis responds to a ‘death signal’ from outside the cell. The normal apoptosis of a macrophage after it has engulfed an invading bacterium leads to priming of cell-mediated immunity, helps to kill the intracellular bacteria and limits harmful tissue inflammation. M. tuberculosis blocks these events, and when the bacteria are ready to exit the macrophage to disseminate, they induce necrosis, not apoptosis, of the cell, which evades stimulation of an immune reaction.

Details

PPM1A is the protein called Protein Phosphatase, Mg2+/Mn2+-dependent 1A. Besides showing that the heightened PPM1A production blocked intrinsic and extrinsic apoptosis, Sun and colleagues examined its mechanism of action. In a variety of elegant experiments using PPM1A overexpression or knockdown mutants, kinome analysis, and a selective inhibitor of PPM1A, the researchers showed that PPM1A controls a downstream effector of apoptosis, the c-Jun N-terminal kinase enzyme, or JNK. Elevated PPM1A levels in overexpression mutants or M. tuberculosis-infected macrophages inactivated JNK. This inactivation could be bypassed by sub-toxic treatment with the JNK agonist anisomysin to induce selective apoptotic killing of M. tuberculosis-infected human macrophages.

Sun is a Research Fellow in the UAB Department of Medicine, Division of Infectious Diseases, mentored by Olaf Kutsch, Ph.D. Besides Sun and Kutsch, authors of the paper, “Mycobacterium tuberculosis exploits the PPM1A signaling pathway to block host macrophage apoptosis,” are Kaitlyn Schaaf, Samuel R. Smith, Alexandra Duverger, Frederic Wagner, Frank Wolschendorf and Andrew O. Westfall, UAB Department of Medicine.

Funding came from National Institutes of Health grants AI104499, AI116188, AI122842 and AI104952, and work in the UAB Center for AIDS Research was funded by NIH grants AI027767 and AR048311.

Back to Top